Registered Office: Biocon Limited 20th KM Hosur Road, Electronic City P.O., Bangalore - 560 100.

www.biocon.com



FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2009

FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2009							
		(Rs. in Lakhs)					
SI. No.	Particulars			Half Year ended 30.09.2009 (Unaudited)		Year ended 31.03.2009 (Audited)	
1.	a. Net Sales / Income from Operations b. Other Operating Income	29,215 895	24,670 672	53,494 1,774	46,788 1,271	91,234 2,754	
2.	Expenditure a. (Increase)/decrease in stock in trade and	(1,667)	(878)	(1,413)	(1,592)	(2,677)	
	Work in Progress		(` '	
	b. Consumption of raw materials c. Purchase of traded goods	15,000 788	11,803 481	25,041 1.191	22,540	39,887 3,201	
	d. Power cost	1,583	1,948	3,183	1,205 3,819	7,122	
	e. Employee cost	2.383	2.100	4.712	4.116	8.200	
	f. Depreciation and amortisation	1,980	1,848	3,943	3,616	7,428	
	g. Other expenditure	4.299	4.050	8,093	6,225	13.637	
	h. Total	24,366	21,352	44,750	39,929	76,798	
3.	Profit from Operations before Other Income,	24,300	21,332	44,730	39,929	70,798	
ا."	Interest & Exceptional Items (1-2)	5,744	3,990	10,518	8,130	17,190	
4.	Other Income	1,134	1,485	1,847	2,513	4,724	
5.	Profit before Interest & Exceptional Items (3+4)	6,878	5,475	12,365	10,643	21,914	
6.	Interest	26	151	101	333	494	
7.	Profit after Interest but before Exceptional Items (5-6)	I	5,324	12,264	10,310	21,420	
8		616	5,324 591			1,040	
	Tax Expense, net of reversals	616	591	1,273	805	1,040	
9.	Net Profit from Ordinary Activities after	6 226	4 777	10.001	0.505	20.200	
10.	Tax but before exceptional items (7-8) Exceptional Items (Net of Tax expense) [Refer note 3 below]	6,236	4,733 (1,380)	10,991	9,505 (3,153)	20,380 (9,201)	
11.		6,236	3,353	10,991	6,352	11,179	
12.	Net Profit from ordinary activities after tax (9+10)	10,000	10,000	10,000	10,000	10,000	
13.	Paid-up equity share capital (Face value of Rs. 5 each)	10,000	10,000	10,000	10,000		
14.	Reserves excluding revaluation reserves a. Earnings per share before Exceptional Items (Face value of Rs. 5 each)					127,393	
	Basic	3.23	2.45	5.69	4.92	10.56	
	Diluted	3.14	2.38	5.54	4.77	10.27	
	 Earnings per share after Exceptional Items (Face value of Rs. 5 each) 						
	Basic	3.23	1.74	5.69	3.29	5.79	
_	Diluted	3.14	1.68	5.54	3.19	5.64	
15.	Public Shareholding						
	- Number of Shares	78,165,024		78,165,024			
	- Percentage of shareholding	39.08%	39.08%	39.08%	39.08%	39.08%	
16.	Promoter and Promoter Group Shareholding a) Pledged / encumbered						
	- Number of Shares	-	-	-	-	-	
	- Percentage of shares (as a % of the total					 	
	shareholding of promoter and promoter group)	-	-	-	-	-	
	 Percentage of shares (as a % of the total share capital of the company) 	-	-	-	-	-	
	b) Non-encumbered						
	- Number of Shares	121,834,976	_	121,834,976	l <u>.</u>	121,834,976	
	- Percentage of Shares (as a % of the total	121,034,9/0	_	121,034,370	· •	121,004,970	
	shareholding of promoter and promoter group)	100,00%	_	100,00%	l .	100.00%	
	Percentage of shares (as a % of the total	100.00%	_	100.00%	l -	100.00 %	
	share capital of the company)	60.92%	_	60.92%	l .	60.92%	
	snare capital of the company)	60.92%	-	60.92%	-	60.929	

CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2009							
	THE PERIOD ENDE	D SEPTE	VIBER 30,	(Rs. in Lakhs)			
SI. No.	Particulars	Quarter ended 30.09.2009 (Unaudited)		Half Year ended 30.09.2009 (Unaudited)		Year ended 31.03.20 (Audited	
1.	a. Net Sales / Income from Operations b. Other Operating Income	57,993 116	44,229 506	107,586 368	70,622 1,022	160,8 1,7	
	b. Other Operating Income	58,109	44,735	107,954	71,644	162,6	
2.	Expenditure			-			
	 a. (Increase)/decrease in stock in trade and Work-in-progress 	(1,251)	(1,879)	(1,546)	(2,789)	(5,4	
	b. Consumption of raw materials	33,943	25,363	61,406	37,610	87,	
	c. Purchase of traded goods	459	296	657	613	2,	
	d. Power cost	1,611	1,955	3,156	3,840	6,	
	e. Employee cost	6,087	4,676	11,735	8,071	17,	
	f. Depreciation and amortisation g. Other expenditure	3,506 5,842	2,904 6,465	6,750 10,738	5,429 9,262	11, 19,	
	h. Total	50,197	39,780	92,896	62,036	139,	
3.	Profit from Operations before Other Income,	7,912	4,955	15,058	9,608	23,	
٦.	Interest & Exceptional Items (1-2)	,,,,,,,,,	4,555	15,050	3,000	25,	
4.	Other Income	1,126	1,038	1,810	1,782	4,	
5.	Profit before Interest & Exceptional Items (3+4)	9,038	5,993	16,868	11,390	27,	
6.	Interest	523	422	1,085	791	1,	
7.	Profit after Interest but before Exceptional Items (5-6)	8,515	5,571	15,783	10,599	26,	
8.	Tax Expense, net of reversals	939	587	2,312	760	1,	
9.	Net Profit from Ordinary Activities after Tax						
	but before exceptional items (7-8)	7,576	4,984	13,471	9,839	24,	
10.	Exceptional Items (Net of Tax expense)	-	(2,545)	-	(5,996)	(14,7	
	[Refer note 3 below]						
11.	Net Profit from ordinary activities	7.55	2 420	42.474	2042	40.	
12.	before minority interest (9+10) Add/(Less): Minority interest [Refer note 4 below]	7,576 (166)	2,439 63	13,471 (297)	3,843 163	10,	
13.	Share of Losses in Associate	(100)	03	(297)	103	'	
14.	Net Profit from ordinary activities after tax (11+12+13)	7,419	2,502	13,174	4,006	9,	
5	Paid-up equity share capital (Face value of Rs. 5 each)	10,000	10,000	10,000	10,000	10,	
6.	Reserves excluding revaluation reserves	10,000		10,000	,	140,	
7.	a. Earnings per share before exceptional items						
	(Face value of Rs. 5 each)						
	Basic	3.84	2.61	6.82	5.18	12	
	Diluted	3.74	2.53	6.64	5.02	12	
	b. Earnings per share after exceptional items						
	(Face value of Rs. 5 each)				2.07	Ι.,	
	Basic Diluted	3.84 3.74	1.29	6.82 6.63	2.07	4	
18.	Public Shareholding	3./4	1.25	0.03	2.00		
۱۰۰۱	- Number of Shares	78,165,024	78,165,024	78,165,024	78,165,024	78,165,	
	- Percentage of shareholding	39.08%	39.08%	39.08%	39.08%	39.0	
19.	Promoter and Promoter Group Shareholding	33.00%	33.0070	35.0070	33.0070] 55.0	
	a) Pledged / encumbered						
	- Number of Shares	-	-	-	-		
	- Percentage of Shares (as a % of the total shareholding		1				
	of shareholding of promoter and promoter group)	-	-	-	-		
	- Percentage of shares (as a % of the total		I				
	share capital of the company)	-	-	-	-		
	b) Non-encumbered	124 024 676	1	124 624 676		121 024	
	- Number of Shares	121,834,976	l -	121,834,976	-	121,834,	
	 Percentage of Shares (as a % of the total shareholding of promoter and promoter group) 	100.00%	I	100.00%		100.0	
	Percentage of shares (as a % of the total share	100.00%	· -	100.00%	-	100.0	
	capital of the company)	60 92%	1	60.92%		60.0	

SEGMENT RESULTS OF CONSOLIDATED RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2009 (Rs. in Lakhs)						
Particulars	Quarter ended 30.09.2009 (Unaudited)		Half Year ended 30.09.2009 (Unaudited)	Half Year ended	Year ended 31.03.2009 (Audited)	
Segment revenue						
a. Pharma	50,689	38,912	93,854	61,029	138,561	
b. Contract Research	7,773	5,579	14,498	10,076	23,594	
Total	58,462	44,491	108,352	71,105	162,155	
Less: Inter-segment revenue	469	262	766	483	1,288	
Net sales	57,993	44,229	107,586	70,622	160,867	
Segment results						
Profit before interest, depreciation and tax						
from each segment						
a. Pharma	14,452	10,096	26,209	18,299	40,244	
b. Contract Research	1,998	998	4,574	1,887	6,646	
Total	16,450	11,094	30,783	20,186	46,890	
Less:Interest	523	422	1,085	791	1,766	
Depreciation and amortisation	3,506	2,904	6,750	5,429	11,025	
Unallocated corporate expenses	5,148	3,740	9,343	6,171	13,542	
Unallocated corporate income	(1,242)	(1,543)	(2,178)	(2,804)	(5,443)	
Profit before tax and exceptional items	8,515	5,571	15,783	10,599	26,000	
Capital employed						
a. Pharma	126,218	106,254	126,218	106,254	113,211	
b. Contract Research	22,509	18,873	22,509	18,873	20,110	
c. Minority Interest	(2,804)	(2,616)	(2,804)	(2,616)	(2,477)	
d. Unallocable	18,580	30,240	18,580	30,240	20,230	
Total capital employed	164,503	152,751	164,503	152,751	151,074	

- 1. The above results have been reviewed by the Audit Committee on October 21, 2009 and approved by the Board of Directors of the Company at their meeting held on October 22, 2009. The financial results of the Company and the consolidated financial results for the quarter ended September 30, 2009 have been subjected to a limited review by the statutory auditors of the Company.
- . The financial statements for AxiCorp GmbH, Germany ('Axicorp') a subsidiary company, are drawn upto June 30, 2009 for the purposes of consolidation. Accordingly, the consolidated results of Biocon for the quarter ended September 30, 2009 include the results of AxiCorp for the period from April 1, 2009 to June 30, 2009. The financial statements of other subsidiaries, joint venture company and associate have been drawn up to the same reporting date as that of the Company, i.e. September 30, 2009.

 September 30, 2009.

 6. The Company operates in a single business segment of pharmaceuticals. accordance with Accounting Standard 21, adjustments having been made for significant transactions during the period from July 1, 2009 to September 30, 2009.
- 30, 2008 and year ended March 31, 2009 include mark to market loss in respect of foreign exchange forward contracts including realized gains / losses incurred on termination / cancellation of the said contracts of Rs 1,380 (net of taxes of Rs 110), Rs. 3,153 (net of taxes of Rs. 270) and Rs 9,401 (net of taxes of Rs 773) in the case of the Company and Rs 2,545 (net of tax of Rs 110), Rs. 5,996 (net of taxes of Rs 270) and Rs 14,919 (net of taxes of Rs 73). in respect of the consolidated financial results, respectively.
- b. Exceptional items for the year ended March 31, 2009 also include write back of unutilised provision for contingencies of Rs 200 relating to transfer of its enzymes business created in the prior year.
- 4. For the quarter and half year ended September 30, 2009 and year ended March 31, 2009, minority interest comprise profits of Rs. 166, Rs. 297 and Rs. 299 attributable to minority shareholders of AxiCorp, net of losses recognized amounting to Rs. Nil, Rs Nil and Rs. 414 pertaining to the losses Biocon Biopharmaceuticals Private Limited, respectively.
- 5. The Company on September 30, 2009, entered into a definitive agreement to purchase the active pharmaceutical ingredient business of IDL Speciality Chemicals Limited. The Company is yet to consummate the transaction pending completion of conditions precedent and accordingly the same has not been recorded as at
- 7. During the quarter ended September 30, 2009, the Company paid dividend of Rs. 3/- per share amounting to Rs. 60 Crores for the year 2008-09 representing 60% dividend.
- a. Exceptional items for the quarter and half year ended September 30, 2009 is Rs NIL. Exceptional items for the quarter and half year ended September 8. In respect of the consolidated financial results, the primary segment reporting has been performed on the basis of business segments. Segments have been identified and reported based on the nature of the products, risks and returns, organizational structure and internal financial reporting system
 - 9. Total number of shareholder complaints pending at the beginning of the quarter was Nil. Complaints received during the quarter were 103. All complaints have been resolved as at September 30, 2009.
 - 10. The prior period/year figures have been reclassified wherever required to conform to the classification of the current quarter

For and on behalf of the Board of Directors

Kiran Mazumdar Shaw

Chairman & Managing Director

Place: Bangalore Date: October 22, 2009